Please login to the form below

Not currently logged in
Email:
Password:

PI3K

This page shows the latest PI3K news and features for those working in and with pharma, biotech and healthcare.

Chi-Med cues up two more regulatory filings in cancer

Chi-Med cues up two more regulatory filings in cancer

Following after its first three drugs are potential first-in-class selective Syk inhibitor HMPL-523, in phase 1 testing for non-Hodgkin’s lymphoma, and a PI3K delta inhibitor

Latest news

More from news
Approximately 1 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2016 Deal Watch November 2016

    development and commercialisation. 45. Infinity Pharmaceuticals/ Verastem. Duvelisib, oral inhibitor of PI3K‐delta and PI3K‐gamma for haematological cancers (p3).

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    970. Infinity / AbbVie. Licence and collaboration. IPI-145 an oral PI3K-delta, gamma inhibitor in Phase III for chronic lymphocytic leukaemia .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics